KR101815030B1 - 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용 - Google Patents

킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용 Download PDF

Info

Publication number
KR101815030B1
KR101815030B1 KR1020147013510A KR20147013510A KR101815030B1 KR 101815030 B1 KR101815030 B1 KR 101815030B1 KR 1020147013510 A KR1020147013510 A KR 1020147013510A KR 20147013510 A KR20147013510 A KR 20147013510A KR 101815030 B1 KR101815030 B1 KR 101815030B1
Authority
KR
South Korea
Prior art keywords
delete delete
drug
peg
pga
chelate complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147013510A
Other languages
English (en)
Korean (ko)
Other versions
KR20140101741A (ko
Inventor
추후이 왕
치아훙 첸
존손 린
진이 첸
웨이추안 리아오
Original Assignee
㈜오리지날 바이오메디칼스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ㈜오리지날 바이오메디칼스 filed Critical ㈜오리지날 바이오메디칼스
Publication of KR20140101741A publication Critical patent/KR20140101741A/ko
Application granted granted Critical
Publication of KR101815030B1 publication Critical patent/KR101815030B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147013510A 2011-11-22 2012-08-23 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용 Active KR101815030B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562663P 2011-11-22 2011-11-22
US61/562,663 2011-11-22
PCT/CN2012/001126 WO2013075394A1 (zh) 2011-11-22 2012-08-23 具有螯合型复合微胞的药物载体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000079A Division KR101885677B1 (ko) 2011-11-22 2012-08-23 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용

Publications (2)

Publication Number Publication Date
KR20140101741A KR20140101741A (ko) 2014-08-20
KR101815030B1 true KR101815030B1 (ko) 2018-01-08

Family

ID=48469042

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147013510A Active KR101815030B1 (ko) 2011-11-22 2012-08-23 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용
KR1020177000079A Active KR101885677B1 (ko) 2011-11-22 2012-08-23 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177000079A Active KR101885677B1 (ko) 2011-11-22 2012-08-23 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용

Country Status (10)

Country Link
EP (1) EP2783679B1 (enExample)
JP (3) JP2015507605A (enExample)
KR (2) KR101815030B1 (enExample)
CN (1) CN103127521B (enExample)
AU (1) AU2012343239B2 (enExample)
CA (1) CA2856501C (enExample)
IL (1) IL232729B (enExample)
IN (1) IN2014MN00936A (enExample)
TW (1) TWI568453B (enExample)
WO (1) WO2013075394A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854927A1 (en) * 2012-08-28 2014-03-06 Original Biomedicals Co., Ltd. A two-part pharmaceutical formulation comprising chelating micelles for control release of drug
CA2851130C (en) * 2012-11-22 2019-10-01 Chia-Hung Chen A pharmaceutical composition used for reducing damage caused by free radicals
WO2015020240A1 (ko) * 2013-08-06 2015-02-12 동국제약 주식회사 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물
CN104627958B (zh) * 2015-01-30 2016-03-16 四川大学 一种稳定性增强的改性纳米粒子及其制备方法
CN104693433B (zh) * 2015-02-04 2017-06-06 国家纳米科学中心 一种聚乙二醇化氨磷汀、制备方法及其用途
CN108495625B (zh) * 2015-11-17 2021-07-27 柏林顿Hc研究集团有限公司 改善对氨基硫醇及其类似物的保护和递送的方法
EP3505154B1 (en) 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
KR102206913B1 (ko) 2018-12-04 2021-01-26 한국생산기술연구원 기능성 물질 전달용 조성물 및 이의 제조 방법
CN109970987B (zh) * 2019-04-11 2021-09-17 中国医学科学院放射医学研究所 Mof材料、纳米载药材料、药物组合物及其应用
KR102520641B1 (ko) * 2020-10-14 2023-04-11 고려대학교 산학협력단 마그네슘 이온을 포함하는 자가조립 복합체
TWI886408B (zh) * 2021-09-09 2025-06-11 原創生醫股份有限公司 用於超音波造影之金屬複合物及其用途
JP7464304B2 (ja) * 2022-04-13 2024-04-09 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション 鉄イオンを含む自己組み立て複合体
KR20240096203A (ko) * 2022-12-19 2024-06-26 고려대학교 산학협력단 코발트, 은, 가돌리늄 및 철 중 어느 하나 이상을 포함하는 자가조립 복합체
KR20240127770A (ko) * 2023-02-16 2024-08-23 고려대학교 산학협력단 치료용 자성 바이오분자-금속이온 자가조립 복합체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107903A2 (en) 2005-04-01 2006-10-12 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
WO2011025036A1 (ja) * 2009-08-31 2011-03-03 ナノキャリア株式会社 粒子組成物及びこれを有する医薬組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432867T2 (de) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood Zubereitung mit gesteuerter freisetzung
JPH10158195A (ja) * 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP4257697B2 (ja) * 2000-09-26 2009-04-22 株式会社東京大学Ｔｌｏ シスプラチン内包高分子ミセルおよびその使用
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
CN100457185C (zh) * 2003-12-10 2009-02-04 株式会社东京大学Tlo 二氨基环己烷合铂(ⅱ)与含聚羧酸链段的嵌段共聚物的配位络合物、其抗肿瘤剂
CA2546057A1 (en) * 2003-12-11 2005-06-23 Schering Aktiengesellschaft Method to improve the efficacy of therapeutic radiolabeled drugs
CA2561380A1 (en) * 2004-03-30 2005-10-13 The University Of Sydney A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
ES2313352T3 (es) * 2004-06-03 2009-03-01 Bracco Research S.A. Ensamblaje de liposomas para uso terapeutico y/o diagnostico.
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
EP1873204B1 (en) * 2005-04-18 2011-09-21 Hiroshi Maeda Polymeric pharmaceutical agent for treatment of cancer and process for production of the same
US8008347B2 (en) * 2006-02-14 2011-08-30 Eastern Virginia Medical School Methoxypolyethylene glycol thioester chelate and uses thereof
US8815833B2 (en) * 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
CN101224187B (zh) * 2008-01-31 2010-07-21 中国医学科学院生物医学工程研究所 双功能聚合物纳米胶束及制备方法及在制备治疗血管再狭窄药物中的应用
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
WO2009117333A1 (en) * 2008-03-17 2009-09-24 University Of Utah Research Foundation Dithiocarbamate metal chelates and methods of making and using thereof
WO2009157279A1 (ja) * 2008-06-24 2009-12-30 ナノキャリア株式会社 シスプラチン配位化合物の液体組成物
CA2728960C (en) * 2008-06-26 2016-04-12 Japan Science And Technology Agency Polymer-metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same
JP5320569B2 (ja) * 2008-06-28 2013-10-23 公益財団法人神奈川科学技術アカデミー 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤
EP2161020A1 (en) * 2008-09-09 2010-03-10 Koninklijke Philips Electronics N.V. Chelating amphiphilic polymers
JP2011105792A (ja) * 2009-11-12 2011-06-02 Japan Science & Technology Agency ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア
WO2012058552A1 (en) * 2010-10-29 2012-05-03 Intezyne Technologies, Incorporated Iron stabilized polymer micelles for drug delivery applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107903A2 (en) 2005-04-01 2006-10-12 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
WO2011025036A1 (ja) * 2009-08-31 2011-03-03 ナノキャリア株式会社 粒子組成物及びこれを有する医薬組成物

Also Published As

Publication number Publication date
TWI568453B (zh) 2017-02-01
AU2012343239B2 (en) 2016-04-28
JP2018021070A (ja) 2018-02-08
JP6224776B2 (ja) 2017-11-01
JP2015507605A (ja) 2015-03-12
IL232729B (en) 2019-06-30
JP2016188236A (ja) 2016-11-04
TW201321027A (zh) 2013-06-01
AU2012343239A1 (en) 2014-06-05
IN2014MN00936A (enExample) 2015-04-24
CN103127521A (zh) 2013-06-05
EP2783679A4 (en) 2015-08-26
KR101885677B1 (ko) 2018-08-06
CA2856501C (en) 2017-01-03
KR20140101741A (ko) 2014-08-20
EP2783679B1 (en) 2018-07-18
EP2783679A1 (en) 2014-10-01
CN103127521B (zh) 2016-10-26
JP6445648B2 (ja) 2018-12-26
CA2856501A1 (en) 2013-05-30
IL232729A0 (en) 2014-07-31
KR20170004044A (ko) 2017-01-10
WO2013075394A1 (zh) 2013-05-30

Similar Documents

Publication Publication Date Title
KR101815030B1 (ko) 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용
US9226967B2 (en) Chelating complex micelles drug carrier
Soares et al. Polymer-hybrid nanoparticles: Current advances in biomedical applications
Cabral et al. Optimization of (1, 2-diamino-cyclohexane) platinum (II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
Sun et al. Bioreducible PAA-g-PEG graft micelles with high doxorubicin loading for targeted antitumor effect against mouse breast carcinoma
Chen et al. DOX-assisted functionalization of green tea polyphenol nanoparticles for effective chemo-photothermal cancer therapy
Xu et al. Reduction-responsive polypeptide micelles for intracellular delivery of antineoplastic agent
CN108938594B (zh) 一种药物复合物及其制备方法与应用
Sun et al. Polymers in the co-delivery of siRNA and anticancer drugs for the treatment of drug-resistant cancers
WO2008112565A2 (en) Method and composition for treating cancer
EP2890400A1 (en) The controlled release method for a pharmaceutical composition composed of chelating complex micelles
WO2022052413A1 (zh) 具有不对称膜结构的载药聚合物囊泡及其制备方法与在制备治疗急性髓系白血病药物中的应用
Pourmadadi et al. Nanoparticles loaded with Daunorubicin as an advanced tool for cancer therapy
CN110804178B (zh) 一种具有谷胱甘肽响应性的纳米载药体系及其制备方法和应用
WO2008130180A1 (en) Preparation of drug delivery systems using ph-sensitive block copolymer and their application
Cheng et al. Cisplatin-cross-linked and oxygen-resupply hyaluronic acid-based nanocarriers for chemo-photodynamic therapy
CA3008095A1 (en) A pharmaceutical composition comprising apatite-based matrix and surface modifying agent
Han et al. Recent advances and perspectives of multifunctional nanogels in biomedical applications
CN112979881A (zh) 促抗癌药摄入的大分子、组合物及其制备抗癌药物的用途
CN113024789B (zh) 一种交联聚合物胶束及其制备方法和应用
CN119405622A (zh) 一种脂质-聚合物纳米药物及其制备方法
Bai et al. Bone-targeted PAMAM micelle to treat bone metastases of lung cancer
TR2024016634A2 (tr) S-ali̇l-l-si̇stei̇n (sac) yüklü nanoparti̇kül tabanli bi̇r formülasyon ve bu formülasyonun üreti̇mi̇ i̇çi̇n bi̇r yöntem

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9